<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05016518</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0424-002</org_study_id>
    <nct_id>NCT05016518</nct_id>
  </id_info>
  <brief_title>Comparison of Quality of Recovery (QoR)-15 Scores</brief_title>
  <official_title>Comparison of Quality of Recovery (QoR)-15 Scores According to the Use of Anesthetics During Total Intravenous Anesthesia in Female Patients Undergoing Thyroid Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gangnam Severance Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Remimazolam is a ultra-short-acting benzodiazepine that is rapidly metabolized in the body by&#xD;
      tissue esterase and not accumulates in the body for long periods of infusion. In addition,&#xD;
      similar to other benzodiazepines, it is possible to reverse the sedation and anesthetic&#xD;
      effects through flumazenil. It has no injection pain and infusion syndrome compared with&#xD;
      propofol. There is no study to investigate overall postoperative functional recovery via&#xD;
      QoR-15 in patients receiving TIVA using remimazolam. The purpose of this study is to&#xD;
      determine whether there is any difference in the quality of postoperative recovery between&#xD;
      propofol-based and remimazolam-based total intravenous anesthesia in female patients&#xD;
      undergoing thyroidectomy. The QoR-15 questionnaire score, pain, nausea/vomiting, and the&#xD;
      frequency of complications are evaluated and compared between the two groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2021</start_date>
  <completion_date type="Anticipated">July 4, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative day 1(POD1) Quality of Recovery(QoR)-15 questionnaire score</measure>
    <time_frame>Time Frame: postoperative day1</time_frame>
    <description>Quality of life will be evaluated using Quality of Recovery(QoR)-15 questionnaire score at postoperative day 1(minimum value : 0, maximum value : 150, the higher the score, the better the result)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative day 2(POD2) Quality of Recovery(QoR)-15 questionnaire score</measure>
    <time_frame>postoperative day2</time_frame>
    <description>Quality of life will be evaluated using Quality of Recovery(QoR)-15 questionnaire score at postoperative day 2(minimum value : 0, maximum value : 150, the higher the score, the better the result)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response time</measure>
    <time_frame>perioperative - until 48hours</time_frame>
    <description>Time from cessation of main anaesthetics to patients' response to verbal command</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tracheal extubation time</measure>
    <time_frame>perioperative - until 48hours</time_frame>
    <description>Time from cessation of main anaesthetics to tracheal extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recovery of self respiration</measure>
    <time_frame>perioperative - until 48hours</time_frame>
    <description>Time from cessation of main anaesthetics to recovery of spontaneous breathing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PACU(post-anesthesia care unit) stay time</measure>
    <time_frame>perioperative - until 48hours</time_frame>
    <description>from entry of PACU to go general ward</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain score</measure>
    <time_frame>at admission to PACU, discharge from PACU, postoperative 6hours</time_frame>
    <description>postoperative pain score measured by 11-point NRS(numerical rating scale) score (minimum : 0, maximum : 11, the lower the score, the lesser pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative nausea and vomiting</measure>
    <time_frame>at admission to PACU, discharge from PACU, postoperative 6hours</time_frame>
    <description>postoperative nausea and vomiting will be evaluated using 2 point scale (yes, no) at admission to PACU, discharge from PACU, postoperative 6hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative sedation score</measure>
    <time_frame>at admission to PACU, discharge from PACU</time_frame>
    <description>monitored through the sedation scale called Richmond Agitation-Sedation Scale(RASS). RASS is a medical scale used to measure the agitation or sedation level of a person.The score ranges from +4 &quot;combative&quot; to -5 &quot;unarousable&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the incidence of administration of postoperative rescue drug</measure>
    <time_frame>perioperative - until 72hours</time_frame>
    <description>administration of analgesic drug and anti-emetic drug for postoperative management</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital stay</measure>
    <time_frame>preoperative - until discharge (usually 48 hours to 72hours)</time_frame>
    <description>days of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative complications</measure>
    <time_frame>preoperative - until discharge (usually 48 hours to 72hours)</time_frame>
    <description>postoperative complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Patients Undergoing Thyroid Surgery for Neoplasm</condition>
  <arm_group>
    <arm_group_label>Propofol group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol based total intravenous anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remimazolam group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remimazolam based total intravenous anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm I (Propofol group)</intervention_name>
    <description>Propfol group will be started and maintained total intravenous anesthesia with propofol and remifentanil under target controlled infusion (TCI) model.</description>
    <arm_group_label>Propofol group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm II (Remimazolam group)</intervention_name>
    <description>Remimazolam group will be started total intravenous anesthesia with remiamazolam at 6 mg/kg/h for induction, and maintained at 0.5-1.5 mg/kg/h and remifentanil under TCI model.</description>
    <arm_group_label>Remimazolam group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        •20≤Age≤65 female Open thyroidectomy ASA-PS I-III&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergic history of any study drug&#xD;
&#xD;
          -  Taking any sedative, opioid, or sleep aid drugs&#xD;
&#xD;
          -  Psychiatric or neurological disorder&#xD;
&#xD;
          -  BMI&gt;30 kg/m2&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Vulnerable patients&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young Song</last_name>
    <role>Principal Investigator</role>
    <affiliation>GangnamSeverance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Young Song</last_name>
    <phone>82-2-2019-4601</phone>
    <email>NEARMYHEART@yuhs.ac</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeong-Yeonn Choi</last_name>
    <phone>82-2-2019-4601</phone>
    <email>CHOIJEONGYEON84@yuhs.ac</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeong-Yeon Choi</last_name>
      <phone>82-2-2019-4601</phone>
      <email>CHOIJEONGYEON84@yuhs.ac</email>
    </contact>
    <contact_backup>
      <last_name>Young Song</last_name>
      <phone>82-2-2019-4601</phone>
      <email>NEARMYHEART@yuhs.ac</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>Young Song</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

